Back to top
more

Exelixis (EXEL)

(Delayed Data from NSDQ)

$40.45 USD

40.45
2,742,968

+0.01 (0.02%)

Updated Sep 18, 2025 04:00 PM ET

After-Market: $40.51 +0.06 (0.15%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.64%
2Buy17.83%
3Hold9.69%
4Sell5.29%
5Strong Sell2.54%
S&P50011.29%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value D Growth D Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 36% (89 out of 245)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Quest Diagnostics Q4 Earnings Preview: What's in Store for the Stock?

by Zacks Equity Research

Quest Diagnostics is likely to have driven strong performances in the key physician and hospital channels in the fourth quarter of 2024.

Zacks Equity Research

EXEL vs. TECH: Which Stock Is the Better Value Option?

by Zacks Equity Research

EXEL vs. TECH: Which Stock Is the Better Value Option?

Urmimala Biswas headshot

4 PEG-Based Value Stocks to Neutralize Trump 2.0-Led Market Volatility

by Urmimala Biswas

Here are four PEG-driven value stocks, WFC, EXEL, DAL and GBX, which qualify our screening criteria.

Zacks Equity Research

Why This 1 Momentum Stock Could Be a Great Addition to Your Portfolio

by Zacks Equity Research

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Kinjel Shah headshot

Merck Falls 9% in 3 Months: Buy, Hold or Sell the Stock?

by Kinjel Shah

We believe investors with a long-term horizon should hold MRK stock, while short-term investors should consider selling it.

Zacks Equity Research

Zacks Industry Outlook Highlights Incyte, BioMarin, Exelixis, Halozyme and Blueprint Medicines

by Zacks Equity Research

Incyte, BioMarin, Exelixis, Halozyme and Blueprint Medicines have been highlighted in this Industry Outlook article.

Zacks Equity Research

Why Exelixis (EXEL) is Poised to Beat Earnings Estimates Again

by Zacks Equity Research

Exelixis (EXEL) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Ekta Bagri headshot

5 Biotech Stocks Worth Adding to Your Portfolio in 2025

by Ekta Bagri

New drug approvals and pipeline progress are likely to help maintain the momentum for the Zacks Biomedical and Genetics industry despite the uncertain macro environment. A strong portfolio and solid pipeline progress position INCY, BMRN, EXEL, HALO and BPMC well in this volatile sector.

Zacks Equity Research

Exelixis Provides Preliminary 2024 Results and Outlook for 2025

by Zacks Equity Research

EXEL reports preliminary 2024 revenues. The company also provides guidance for 2025 and other pipeline updates.

Zacks Equity Research

Why Exelixis (EXEL) is a Top Value Stock for the Long-Term

by Zacks Equity Research

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Zacks Equity Research

FDA Updates EXEL on Previously Scheduled ODAC Meeting for Cabozantinib

by Zacks Equity Research

EXEL's sNDA seeking approval of cabozantinib for the treatment of pancreatic neuroendocrine tumors will not be discussed at an ODAC.

Zacks Equity Research

Exelixis Stock Surges 50% in a Year: Is There Room for Further Growth?

by Zacks Equity Research

EXEL's shares surge 50% in a year on the back of the strong performance of its lead drug Cabometyx. We are optimistic about the stock as we believe there is room for further growth.

Zacks Equity Research

Are You a Value Investor? This 1 Stock Could Be the Perfect Pick

by Zacks Equity Research

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Zacks Equity Research

EXEL vs. INCY: Which Stock Should Value Investors Buy Now?

by Zacks Equity Research

EXEL vs. INCY: Which Stock Is the Better Value Option?

Zacks Equity Research

Is First Trust NYSE Arca Biotechnology ETF (FBT) a Strong ETF Right Now?

by Zacks Equity Research

Smart Beta ETF report for FBT

Zacks Equity Research

The Zacks Analyst Blog Highlights Sarepta Therapeutics, ADMA Biologics, Exelixis and Alnylam

by Zacks Equity Research

Sarepta Therapeutics, ADMA Biologics, Exelixis and Alnylam are included in this Analyst Blog.

Ekta Bagri headshot

4 Biotech Stocks Most Wall Street Analysts Are Bullish About

by Ekta Bagri

Here, we present four biotech stocks, namely SRPT, ADMA, EXEL and ALNY, which most Wall Street analysts are optimistic about. These companies have upside potential for 2025, backed by strong fundamentals.

Kinjel Shah headshot

Merck to End Development of Two Cancer Candidates: Time to Sell?

by Kinjel Shah

We believe investors with a long-term horizon should stay invested in MRK stock, while short-term investors should consider selling the same.

Zacks Equity Research

Pfizer Stock Up 5% as 2025 Guidance Meets Investor Expectations

by Zacks Equity Research

Pfizer projects total revenues between $61.0 and $64.0 billion with EPS in the range of $2.80 to $3.00.

Zacks Equity Research

SpringWorks Therapeutics (SWTX) Up 14.5% Since Last Earnings Report: Can It Continue?

by Zacks Equity Research

SpringWorks Therapeutics (SWTX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Zacks Equity Research

Why This 1 Value Stock Could Be a Great Addition to Your Portfolio

by Zacks Equity Research

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Zacks Equity Research

Lilly Announces New $15B Stock Buyback Plan, Ups Dividend by 15%

by Zacks Equity Research

LLY's board approves a new $15B stock buyback plan and announces a 15% increase in its quarterly dividend.

Zacks Equity Research

Should You Invest in the First Trust NYSE Arca Biotechnology ETF (FBT)?

by Zacks Equity Research

Sector ETF report for FBT

Zacks Equity Research

Exelixis (EXEL) is an Incredible Growth Stock: 3 Reasons Why

by Zacks Equity Research

Exelixis (EXEL) is well positioned to outperform the market, as it exhibits above-average growth in financials.

Zacks Equity Research

EXEL or INCY: Which Is the Better Value Stock Right Now?

by Zacks Equity Research

EXEL vs. INCY: Which Stock Is the Better Value Option?